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In “Impact of the M184V/I Mutation on the Efficacy of Abacavir/
Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced 
Patients” Open Forum Infectious Diseases, Volume 6, Issue 10, 
October 2019, ofz330,  https://doi.org/10.1093/ofid/ofz330, the 
surname of a co-author, Dominique Costagliola, was misspelled. 
This was corrected in the new version of the manuscript.
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